Considering that pancreatic ILC2s could promote anti-tumor response of CD8 T cells upon α-PD-1 treatment, it will be interesting to investigate the role of Gal-1 on pancreatic ILC2s during pancreatic cancer.13 Here, CD8A is linked to neoplasm.